Influencia de las modificaciones de la glucemia y de la hipotermia en el volumen de infarto cerebral en la rata

Tesis Univ. Complutense de Madrid, 1996Introducción: no existe un tratamiento efectivo del infarto cerebral ni se conoce bien el efecto de las variaciones de glucemia o de la hipotermia en el mismo. Objetivos: determinar el efecto de las variaciones de glucemia y de la hipotermia en un modelo de infarto cerebral experimental en la rata. Material y métodos: se utilizo el modelo de infarto cerebral en la rata por oclusión microquirúrgica de la arteria cerebral media según técnica de tamura en ratas y posteriormente se provoco hiperglucemia (n=10), normoglucemia (n=7) o hipoglucemia (n=8) mediante insulina i.v., y a otro grupo se le provoco la hipoglucemia previamente al infarto cerebral (n=10). En un segundo experimento se aplico hipotermia (n=21) o normotermia (n=21) en el mismo modelo. Se mantuvieron las condiciones experimentales durante las 24 horas siguientes a la instauración del infarto cerebral. A continuación se sacrifico el animal y se midió en preparaciones histologicas (hematoxilina-eosina) el volumen de infarto cerebral. Conclusión: la hipotermia produce menores volúmenes de infarto que la normotermia. La hipoglucemia aplicada desde antes del infarto cerebral ocasiona menores volúmenes de infarto que la hipoglucemia o hiperglucemia que se aplican a las dos horas de producir el infarto cerebral.Fac. de MedicinaTRUEpu

Can plasma α-Synuclein help us to differentiate parkinson’s disease from essential tremor?

Background: Studies have revealed controversial results regarding the diagnostic accuracy of plasma α-synuclein levels in patients with Parkinson’s disease (PD). This study was aimed to analyze the diagnostic accuracy of plasma α-synuclein in PD versus healthy controls and patients with essential tremor (ET). Methods: In this cross-sectional study, we included de novo (n = 19) and advanced PD patients [OFF (n = 33), and On (n = 35) states], patients with ET (n = 19), and controls (n = 35). The total plasma α-synuclein levels were determined using an ELISA sandwich method. We performed adjusted multivariate regression analysis to estimate the association of α-synuclein levels with group conditions [controls, ET, and de novo, OFF and ON-PD]. We studied the diagnostic accuracy of plasma α-synuclein using the area under the curve (AUC). Results: The plasma α-synuclein levels were higher in controls compared to PD and ET (p < 0.0001), discriminating de novo PD from controls (AUC = 0.74, 95% CI 0.60–0.89), with a trend towards in advanced PD (OFF state) from ET (AUC = 0.69, 95% CI 0.53–0.84). Conclusions: This is the first study examining and comparing plasma α-synuclein levels in ET vs. PD and controls. Preliminary findings suggest that plasma α-synuclein levels might help to discriminate de novo and advanced PD from controls and ET.Junta de Castilla y León is acknowledged for funding through the Biomedicine open project call (Ref. BIO/BU06/14

Influencia de las modificaciones de la glucemia y de la hipotermia en el volumen de infarto cerebral en la rata

Introducción: no existe un tratamiento efectivo del infarto cerebral ni se conoce bien el efecto de las variaciones de glucemia o de la hipotermia en el mismo. Objetivos: determinar el efecto de las variaciones de glucemia y de la hipotermia en un modelo de infarto cerebral experimental en la rata. Material y métodos: se utilizo el modelo de infarto cerebral en la rata por oclusión microquirúrgica de la arteria cerebral media según técnica de tamura en ratas y posteriormente se provoco hiperglucemia (n=10), normoglucemia (n=7) o hipoglucemia (n=8) mediante insulina i.v., y a otro grupo se le provoco la hipoglucemia previamente al infarto cerebral (n=10). En un segundo experimento se aplico hipotermia (n=21) o normotermia (n=21) en el mismo modelo. Se mantuvieron las condiciones experimentales durante las 24 horas siguientes a la instauración del infarto cerebral. A continuación se sacrifico el animal y se midió en preparaciones histologicas (hematoxilina-eosina) el volumen de infarto cerebral. Conclusión: la hipotermia produce menores volúmenes de infarto que la normotermia. La hipoglucemia aplicada desde antes del infarto cerebral ocasiona menores volúmenes de infarto que la hipoglucemia o hiperglucemia que se aplican a las dos horas de producir el infarto cerebral

Plasma acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol in Parkinson's disease and essential tremor. A case control biomarker study

[Background and purpose]: Given the overlapping clinical manifestations and pathology, the differentiation between essential tremor (ET) and Parkinson's disease (PD) is difficult. Our aims were to examine the plasma metabolomics profiling and their association with motor and non-motor symptoms (NMS) in patients with PD, and to determine differences between de novo PD compared to moderate-advanced PD vs. controls and patients with ET.[Methods]: Plasma samples were collected from 137 subjects including 35 age matched controls, 29 NOVO-PD, 35 PD and 38 ET patients. PD severity, motor and NMS including cognitive function were assessed using the UPDRS, NMS and PD cognitive rating scales, respectively. Metabolomics analysis was performed by UPLC-ESI-QToF-MS followed by unsupervised multivariate statistics. The area under the curve of the biomarkers according to distribution of their concentrations and the diagnosis of PD (NOVO-PD, advanced PD) vs ET and healthy controls was used as a measurement of diagnostic ability.[Results]: Several acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol (THS) presented good predictive accuracy (AUC higher than 0.8) for differentiating de novo PD and advanced PD from controls and ET, suggesting an alteration in the lipid oxidation pathway. In multivariate regression analysis, metabolite levels were not significantly associated with motor and NMS severity in PD.[Conclusions]: Diverse acyl-carnitines, bilirubin, tyramine and some adrenal gland derived metabolites are suggested as potential biomarkers able to distinguish between PD from controls and ET.This work was supported by Junta de Castilla y León (BIO/BU06/14)

Plasma acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol in Parkinson's disease and essential tremor. A case control biomarker study

Background and purpose Given the overlapping clinical manifestations and pathology, the differentiation between essential tremor (ET) and Parkinson's disease (PD) is difficult. Our aims were to examine the plasma metabolomics profiling and their association with motor and non-motor symptoms (NMS) in patients with PD, and to determine differences between de novo PD compared to moderate-advanced PD vs. controls and patients with ET. Methods Plasma samples were collected from 137 subjects including 35 age matched controls, 29 NOVO-PD, 35 PD and 38 ET patients. PD severity, motor and NMS including cognitive function were assessed using the UPDRS, NMS and PD cognitive rating scales, respectively. Metabolomics analysis was performed by UPLC-ESI-QToF-MS followed by unsupervised multivariate statistics. The area under the curve of the biomarkers according to distribution of their concentrations and the diagnosis of PD (NOVO-PD, advanced PD) vs ET and healthy controls was used as a measurement of diagnostic ability. Results Several acyl-carnitines, bilirubin, tyramine and tetrahydro-21-deoxycortisol (THS) presented good predictive accuracy (AUC higher than 0.8) for differentiating de novo PD and advanced PD from controls and ET, suggesting an alteration in the lipid oxidation pathway. In multivariate regression analysis, metabolite levels were not significantly associated with motor and NMS severity in PD. Conclusions Diverse acyl-carnitines, bilirubin, tyramine and some adrenal gland derived metabolites are suggested as potential biomarkers able to distinguish between PD from controls and ET.This work was supported by Junta de Castilla y León (BIO/BU06/14)

Impact of COVID-19 outbreak on ischemic stroke admissions and in-hospital mortality in North-West Spain

Background and purpose Spain has been one of the countries heavily stricken by COVID-19. But this epidemic has not affected all regions equally. We analyzed the impact of the COVID-19 pandemic on hospital stroke admissions and in-hospital mortality in tertiary referral hospitals from North-West Spain.Methods Spanish multicenter retrospective observational study based on data from tertiary hospitals of the NORDICTUS network. We recorded the number of patients admitted for ischemic stroke between 30 December 2019 and 3 May 2020, the number of IVT and EVT procedures, and in-hospital mortality.Results In the study period, 2737 patients were admitted with ischemic stroke. There was a decrease in the weekly mean admitted patients during the pandemic (124 vs. 173, p<0.001). In-hospital mortality of stroke patients increased significantly (9.9% vs. 6.5%, p = 0.003), but there were no differences in the proportion of IVT (17.3% vs. 16.1%, p = 0.405) or EVT (22% vs. 23%, p = 0.504).Conclusion We found a decrease in the number of ischemic stroke admissions and an increase in in-hospital mortality during the COVID-19 epidemic in this large study from North-West Spain. There were regional changes within the network, not fully explained by the severity of the pandemic in different regions.Peer reviewe

Impact of COVID‐19 outbreak in reperfusion therapies of acute ischemic stroke in North‐West Spain

Since the first reported case in early December 2019, severe acute respiratory coronavirus 2 (SARS‐CoV‐2) infection, known as Coronavirus Disease 2019 (COVID‐19), has spread all over the world (1‐3). As of June 4th, more than 6 million cases and 350,000 deaths have been reported worldwide (4). Treating these patients and containing the outbreak has become the main priority in any center, arising the risk of possible collateral damage on patients with other acute diseases due to the collapse of the pre‐ and intra‐hospital emergency care systems.Peer reviewe